1. Palleroni NJaB, J. F. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol. 1993;43(3):606-9.
2. Hugh R, Ryschenkow E. Pseudomonas maltophilia, an alcaligenes-like species. J Gen Microbiol. 1961;26:123-32.
3. Hugh R LE. A description of the type strain of Pseudomonas maltophilia. Int Bull Bacteriol Nomencl Taxon 1963;13:133–8.
4. Komagata K YY, Tamagawa V, Ohyama A. Pseudomonas melanogena Iizuka and Komagata 1963, a later subjective synonym of Pseudomonas maltophilia Hugh and Ryschenkow 1960. Int J
Syst Bacteriol. 1974;24:242-7.
5. Palleroni N J KR, Contopoulou R, Doudoroff M. Nucleic acid homologies in the genus Pseudomonas. Int J Syst Bacteriol. 1973;23:333-9.
6. Swings J, P. De Vos, M. Van den Mooter, and J. De Ley. Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int
J Syst Bacteriol. 1983;33(2):409-13.
7. Singer E, J. Debette, A. Lepretre, and J. Swings. Comparative esterase electrophoretic polymorphism and phenotypic analysis of Xanthomonas maltophilia and related strains. Syst Appl Mic-
robiol. 1994;17(1):387-94.
8. Palleroni NJ. Pseudomonas Migula. In Krieg N.R. and and Holt JG, editor: The Williams & Wilkins Co., Baltimore, Md. ; 1894. 141-19 p.
9. Bradbury JFp. Genus II. Xanthomonas, . In: (ed.) INRKaJGH, editor. Bergey’s manual of systematic bacteriology. 1: The Williams & Wilkins Co., Baltimore, Md; 1984. p. 199-210.
10. Nesme X VM, Orso S, Hoste B and Swings J. Diversity and genetic relatedness with genera Xanthomonas and Stenotrophomonas using restriction endonuclease site differences of PCR-amp-
lified 16S rRNA gene. Syst Appl Microbiol. 1995;18(1):127-35.
11. Drancourt M, C. Bollet, and D. Raoult. Stenotrophomonas africana sp. nov., an opportunistic human pathogen in Africa. . Int J Syst Bacteriol. 1997;47(1):160-3.
12. Mahdi O, Eklund B, Fisher N. Laboratory culture and maintenance of Stenotrophomonas maltophilia. Curr Protoc Microbiol. 2014;32:Unit 6F 1.
13. de la Maza LM PM, Bittencourt CE, Peterson EM Color Atlas of Medical Bacteriology, Third ed. Washington DC: ASM Press; 2020.
14. Huang TP, Somers EB, Wong AC. Differential biofilm formation and motility associated with lipopolysaccharide/exopolysaccharide-coupled biosynthetic genes in Stenotrophomonas maltop-
hilia. J Bacteriol. 2006;188(8):3116-20.
15. Wu CJ, Chen Y, Li LH, Wu CM, Lin YT, Ma CH, et al. Roles of SmeYZ, SbiAB, and SmeDEF Efflux Systems in Iron Homeostasis of Stenotrophomonas maltophilia. Microbiol Spectr.
2022;10(3):e0244821.
16. Esposito A, Pompilio A, Bettua C, Crocetta V, Giacobazzi E, Fiscarelli E, et al. Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and
Phenotypic Population Study. Front Microbiol. 2017;8:1590.
17. de Oliveira-Garcia D, Dall’Agnol M, Rosales M, Azzuz AC, Martinez MB, Giron JA. Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia. Emerg Infect
Dis. 2002;8(9):918-23.
18. Giltner CL, Nguyen Y, Burrows LL. Type IV pilin proteins: versatile molecular modules. Microbiol Mol Biol Rev. 2012;76(4):740-72.
19. Bayer-Santos E, Cenens W, Matsuyama BY, Oka GU, Di Sessa G, Mininel IDV, et al. The opportunistic pathogen Stenotrophomonas maltophilia utilizes a type IV secretion system for
interbacterial killing. PLoS Pathog. 2019;15(9):e1007651.
20. Nas MY, White RC, DuMont AL, Lopez AE, Cianciotto NP. Stenotrophomonas maltophilia Encodes a VirB/VirD4 Type IV Secretion System That Modulates Apoptosis in Human Cells and
Promotes Competition against Heterologous Bacteria, Including Pseudomonas aeruginosa. Infect Immun. 2019;87(9).
21. Sun E, Liang G, Wang L, Wei W, Lei M, Song S, et al. Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms. Braz J Infect Dis. 2016;20(4):365-73.
22. Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. Appl Environ Microbiol. 2013;79(23):7116-21.
23. Gonzalez JF, Hahn MM, Gunn JS. Chronic biofilm-based infections: skewing of the immune response. Pathog Dis. 2018;76(3).
24. Flores-Trevino S, Bocanegra-Ibarias P, Camacho-Ortiz A, Morfin-Otero R, Salazar-Sesatty HA, Garza-Gonzalez E. Stenotrophomonas maltophilia biofilm: its role in infectious diseases. Expert
Rev Anti Infect Ther. 2019;17(11):877-93.
25. Dai D, Raskin L, Xi C. The effect of interactions between a bacterial strain isolated from drinking water and a pathogen surrogate on biofilms formation diverged under static vs flow conditi-
ons. J Appl Microbiol. 2017;123(6):1614-27.
26. Mikhailovich V, Heydarov R, Zimenkov D, Chebotar I. Stenotrophomonas maltophilia virulence: a current view. Front Microbiol. 2024;15:1385631.
27. Lin CW, Huang YW, Hu RM, Yang TC. SmeOP-TolCSm efflux pump contributes to the multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2014;58(4):2405-
8.
28. Lin YT, Huang YW, Chen SJ, Chang CW, Yang TC. The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in
mice. Antimicrob Agents Chemother. 2015;59(7):4067-73.
29. Youenou B, Favre-Bonte S, Bodilis J, Brothier E, Dubost A, Muller D, et al. Comparative Genomics of Environmental and Clinical Stenotrophomonas maltophilia Strains with Different Anti-
biotic Resistance Profiles. Genome Biol Evol. 2015;7(9):2484-505.
30. Trifonova A, Strateva T. Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors. Infect Dis (Lond). 2019;51(3):168-78.
31. Yero D, Huedo P, Conchillo-Sole O, Martinez-Servat S, Mamat U, Coves X, et al. Genetic Variants of the DSF Quorum Sensing System in Stenotrophomonas maltophilia Influence Virulence
and Resistance Phenotypes Among Genotypically Diverse Clinical Isolates. Front Microbiol. 2020;11:1160.
32. Huang TP, Lee Wong AC. Extracellular fatty acids facilitate flagella-independent translocation by Stenotrophomonas maltophilia. Res Microbiol. 2007;158(8-9):702-11.
33. Huedo P, Yero D, Martinez-Servat S, Ruyra A, Roher N, Daura X, et al. Decoding the genetic and functional diversity of the DSF quorum-sensing system in Stenotrophomonas maltophilia.
Front Microbiol. 2015;6:761.
34. Alcaraz E, Ghiglione B, Pineda MV, Mangano A, Di Conza J, Passerini de Rossi B. AmpR is a dual regulator in Stenotrophomonas maltophilia with a positive role in beta-lactam resistance and
a negative role in virulence, biofilm and DSF production. Res Microbiol. 2022;173(3):103917.
35. Martinez P, Huedo P, Martinez-Servat S, Planell R, Ferrer-Navarro M, Daura X, et al. Stenotrophomonas maltophilia responds to exogenous AHL signals through the LuxR solo SmoR
(Smlt1839). Front Cell Infect Microbiol. 2015;5:41.
36. Devos S, Van Oudenhove L, Stremersch S, Van Putte W, De Rycke R, Van Driessche G, et al. The effect of imipenem and diffusible signaling factors on the secretion of outer membrane vesicles
and associated Ax21 proteins in Stenotrophomonas maltophilia. Front Microbiol. 2015;6:298.
37. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 2021;34(3):e0003019.
38. Patterson SB, Mende K, Li P, Lu D, Carson ML, Murray CK, et al. Stenotrophomonas maltophilia infections: Clinical characteristics in a military trauma population. Diagn Microbiol Infect
Dis. 2020;96(2):114953.
39. Diez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, et al. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic
fibrosis patients. Int J Antimicrob Agents. 2019;53(1):84-8.
40. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front
Microbiol. 2015;6:893.
41. Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc. 1992;91(12):1170-6.
42. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2-41.
43. Herrera-Heredia SA, Pezina-Cantu C, Garza-Gonzalez E, Bocanegra-Ibarias P, Mendoza-Olazaran S, Morfin-Otero R, et al. Risk factors and molecular mechanisms associated with trimet-
hoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico. J Med Microbiol. 2017;66(8):1102-9.
44. McDaniel MS, Schoeb T, Swords WE. Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections. Infect Immun. 2020;88(4).
45. Gallagher T, Phan J, Oliver A, Chase AB, England WE, Wandro S, et al. Cystic Fibrosis-Associated Stenotrophomonas maltophilia Strain-Specific Adaptations and Responses to pH. J Bacteriol.
2019;201(7).
46. Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, et al. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017;50(5).
47. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin
Microbiol Infect. 2012;18(3):E37-45.
48. Weinstein MP, Lewis JS, 2nd. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes. J
Clin Microbiol. 2020;58(3).
49. Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist.
2022;4(3):dlac040.
50. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infec-
tions. Clin Infect Dis. 2024.
51. Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, et al. Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infe-
ctions in Intensive Care Unit Patients. Clin Infect Dis. 2021;72(11):2021-4.
52. Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for
SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments. PLoS One. 2016;11(3):e0152132.
53. Kim HR, Lee D, Eom YB. Anti-biofilm and Anti-Virulence Efficacy of Celastrol Against Stenotrophomonas maltophilia. Int J Med Sci. 2018;15(6):617-27.
54. W.H. B. Three bacterial plant pathogens: Phytomonas earyophylli sp.n., Phytomonas alliicola sp.n., and Phytomonas manihotis (Arthaud-Berthet et Sondar) Viégas. Phytopathology 1942;32:141-
9.
55. Yabuuchi E, Kosako Y, Oyaizu H, Yano I, Hotta H, Hashimoto Y, et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the
new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol. 1992;36(12):1251-75.
56. Yabuuchi E, Kosako Y, Yano I, Hotta H, Nishiuchi Y. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. Nov.: Proposal of Ralstonia pickettii (Ralston, Palleroni and
Doudoroff 1973) comb. Nov., Ralstonia solanacearum (Smith 1896) comb. Nov. and Ralstonia eutropha (Davis 1969) comb. Nov. Microbiol Immunol. 1995;39(11):897-904.
57. Coenye T, Vandamme P. Diversity and significance of Burkholderia species occupying diverse ecological niches. Environ Microbiol. 2003;5(9):719-29.
58. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkhol-
deria multivorans sp. nov. Int J Syst Bacteriol. 1997;47(4):1188-200.
59. Coenye T, Mahenthiralingam E, Henry D, LiPuma JJ, Laevens S, Gillis M, et al. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and
cystic fibrosis-related isolates. Int J Syst Evol Microbiol. 2001;51(Pt 4):1481-90.
60. Zhang L, Song J, Xie G. [Identification of the Burkholderia cepacia complex genomovars and their virulence in an alfalfa infection model]. Wei Sheng Wu Xue Bao. 2008;48(11):1445-50.
61. Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M, et al. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic
fibrosis patients. Int J Syst Evol Microbiol. 2001;51(Pt 2):271-9.
62. Balandreau J, Viallard V, Cournoyer B, Coenye T, Laevens S, Vandamme P. Burkholderia cepacia genomovar III Is a common plant-associated bacterium. Appl Environ Microbiol.
2001;67(2):982-5.
63. Parfitt KM, Green AE, Connor TR, Neill DR, Mahenthiralingam E. Identification of two distinct phylogenomic lineages and model strains for the understudied cystic fibrosis lung pathogen
Burkholderia multivorans. Microbiology (Reading). 2023;169(8).
64. Fainardi V, Neglia C, Muscara M, Spaggiari C, Tornesello M, Grandinetti R, et al. Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis. Children (Basel). 2022;9(9).
65. Seelman SL, Bazaco MC, Wellman A, Hardy C, Fatica MK, Huang MJ, et al. Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States – 2017-2018.
Epidemiol Infect. 2022;150:e154.
66. Nierman WC, DeShazer D, Kim HS, Tettelin H, Nelson KE, Feldblyum T, et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A. 2004;101(39):14246-51.
67. Van Zandt KE, Greer MT, Gelhaus HC. Glanders: an overview of infection in humans. Orphanet J Rare Dis. 2013;8:131.
68. Whitlock GC, Estes DM, Torres AG. Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett. 2007;277(2):115-22.
69. Derbyshire JB. The eradication of glanders in Canada. Can Vet J. 2002;43(9):722-6.
70. Georgiades C, Fishman EK. Clinical image. Glanders disease of the liver and spleen: CT evaluation. J Comput Assist Tomogr. 2001;25(1):91-3.
71. Neubauer H, Sprague LD, Zacharia R, Tomaso H, Al Dahouk S, Wernery R, et al. Serodiagnosis of Burkholderia mallei infections in horses: state-of-the-art and perspectives. J Vet Med B Infect
Dis Vet Public Health. 2005;52(5):201-5.
72. Tomaso H, Scholz HC, Al Dahouk S, Eickhoff M, Treu TM, Wernery R, et al. Development of a 5’-nuclease real-time PCR assay targeting fliP for the rapid identification of Burkholderia mallei
in clinical samples. Clin Chem. 2006;52(2):307-10.
73. Tiyawisutsri R, Peacock SJ, Langa S, Limmathurotsakul D, Cheng AC, Chierakul W, et al. Antibodies from patients with melioidosis recognize Burkholderia mallei but not Burkholderia
thailandensis antigens in the indirect hemagglutination assay. J Clin Microbiol. 2005;43(9):4872-4.
74. Gilmore G, Barnes J, Ketheesan N, Norton R. Use of antigens derived from Burkholderia pseudomallei, B. thailandensis, and B. cepacia in the indirect hemagglutination assay for melioidosis.
Clin Vaccine Immunol. 2007;14(11):1529-31.
75. Verma RD, Venkateswaran KS, Sharma JK, Agarwal GS. Potency of partially purified malleo-proteins for mallein test in the diagnosis of glanders in equines. Vet Microbiol. 1994;41(4):391-7.
76. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Anti-
microb Chemother. 2004;54(6):1134-8.
77. Estes DM, Dow SW, Schweizer HP, Torres AG. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther. 2010;8(3):325-38.
78. Whitmore A, Krishnaswami CS. A Hitherto Undescribed Infective Disease in Rangoon. Ind Med Gaz. 1912;47(7):262-7.
79. Stanton A. T. FW. Melioidosis, a New Disease of the Tropics. . Trans Fourth Congr Far East Assoc Trop Med. 1921; 2:196–8.
80. McCormick JB, Weaver RE, Hayes PS, Boyce JM, Feldman RA. Wound infection by an indigenous Pseudomonas pseudomallei-like organism isolated from the soil: case report and epidemio-
logic study. J Infect Dis. 1977;135(1):103-7.
81. Nussbaum JJ, Hull DS, Carter MJ. Pseudomonas pseudomallei in an anopthalmic orbit. Arch Ophthalmol. 1980;98(7):1224-5.
82. Glass MB, Steigerwalt AG, Jordan JG, Wilkins PP, Gee JE. Burkholderia oklahomensis sp. nov., a Burkholderia pseudomallei-like species formerly known as the Oklahoma strain of Pseudomonas
pseudomallei. Int J Syst Evol Microbiol. 2006;56(Pt 9):2171-6.
83. Wuthiekanun V, Dance DA, Wattanagoon Y, Supputtamongkol Y, Chaowagul W, White NJ. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med
Microbiol. 1990;33(2):121-6.
84. Lowe P, Engler C, Norton R. Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol. 2002;40(12):4625-7.
85. Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob
Chemother. 1989;24(3):295-309.
86. White NJ. Melioidosis. Lancet. 2003;361(9370):1715-22.
87. Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazi-
dime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis. 2001;33(1):29-34.
88. Dance D. Treatment and prophylaxis of melioidosis. Int J Antimicrob Agents. 2014;43(4):310-8.
89. McLeod C, Morris PS, Bauert PA, Kilburn CJ, Ward LM, Baird RW, et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern
Territory of Australia and review of the literature. Clin Infect Dis. 2015;60(1):21-6.
90. Martina P, Bettiol M, Vescina C, Montanaro P, Mannino MC, Prieto CI, et al. Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J Clin Microbiol.
2013;51(1):339-44.
91. Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821-30.
92. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol. 2005;3(2):144-56.
93. Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health. 2014;2:145.
94. Syed I, Wooten RM. Interactions Between Pathogenic Burkholderia and the Complement System: A Review of Potential Immune Evasion Mechanisms. Front Cell Infect Microbiol.
2021;11:701362.
95. Olland A, Falcoz PE, Kessler R, Massard G. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg.
2011;13(6):631-4.
96. Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob.
2019;18(1):7.
97. Henry D, Campbell M, McGimpsey C, Clarke A, Louden L, Burns JL, et al. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients
with cystic fibrosis. J Clin Microbiol. 1999;37(4):1004-7.
98. Bender JK, Haller S, Pfeifer Y, Hogardt M, Hunfeld KP, Thurmer A, et al. Combined Clinical, Epidemiological, and Genome-Based Analysis Identified a Nationwide Outbreak of Burkhol-
deria cepacia Complex Infections Caused by Contaminated Mouthwash Solutions. Open Forum Infect Dis. 2022;9(5):ofac114.
99. Brisse S, Stefani S, Verhoef J, Van Belkum A, Vandamme P, Goessens W. Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the
Burkholderia cepacia complex. J Clin Microbiol. 2002;40(5):1743-8.
100. Shelly DB, Spilker T, Gracely EJ, Coenye T, Vandamme P, LiPuma JJ. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J
Clin Microbiol. 2000;38(8):3112-5.
101. Fehlberg LC, Andrade LH, Assis DM, Pereira RH, Gales AC, Marques EA. Performance of MALDI-ToF MS for species identification of Burkholderia cepacia complex clinical isolates. Diagn
Microbiol Infect Dis. 2013;77(2):126-8.
102. Gautam V, Sharma M, Singhal L, Kumar S, Kaur P, Tiwari R, et al. MALDI-TOF mass spectrometry: An emerging tool for unequivocal identification of non-fermenting Gram-negative bacilli.
Indian J Med Res. 2017;145(5):665-72.
103. Ryan MP, Pembroke JT, Adley CC. Ralstonia pickettii: a persistent gram-negative nosocomial infectious organism. J Hosp Infect. 2006;62(3):278-84.
104. Waugh JB GW, Gaggar A. . Incidence, relevance and response for Ralsfonia respiratory infections. . Clin Lab Sci. 2010 23(2):99-106.
105. Orme J, Rivera-Bonilla T, Loli A, Blattman NN. Native Valve Endocarditis due to Ralstonia pickettii: A Case Report and Literature Review. Case Rep Infect Dis. 2015;2015:324675.
106. Stryjewski ME, LiPuma JJ, Messier RH, Jr., Reller LB, Alexander BD. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Micro-
biol. 2003;41(5):2255-7.
107. Walsh C W, T. In: Antibiotics: Challenges, Mechanisms, Opportunities. Washington, DC.: ASM Press; 2016.
108. Lu DC, Chang SC, Chen YC, Luh KT, Hsieh WC. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood. Diagn Microbiol
Infect Dis. 1997;28(4):187-91.
109. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or
ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1999;43(2):213-7.
110. Vermis K, Vandamme PA, Nelis HJ. Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. J Appl
Microbiol. 2003;95(6):1191-9.
111. Liang M, Chen R, Xian Y, Hu J, Hou X, Wang B, et al. Determination of bongkrekic acid and isobongkrekic acid in rice noodles by HPLC-Orbitrap HRMS technology using magnetic halloysite
nanotubes. Food Chem. 2021;344:128682.
112. Zhang H, Guo Y, Chen L, Liu Z, Liang J, Shi M, et al. Epidemiology of foodborne bongkrekic acid poisoning outbreaks in China, 2010 to 2020. PLoS One. 2023;18(1):e0279957.
113. Jiao Z, Kawamura Y, Mishima N, Yang R, Li N, Liu X, et al. Need to differentiate lethal toxin-producing strains of Burkholderia gladioli, which cause severe food poisoning: description of B.
gladioli pathovar cocovenenans and an emended description of B. gladioli. Microbiol Immunol. 2003;47(12):915-25.
114. Suo DC, Xiao, Z. M., Zhang, J., Wang, S., Feng, Y. C., Guan, X., Li, Y., Fan, X. Determination of bongkrekic acid and toxoflavin in fermented straw feed by liquid chromatography tandem
quadrupole linear ion trap mass spectrometry. China Feed. 2022;19 93–8.
115. Gao B, Deng H, Wang Y, Zhang C, Zhu J. Detection methods and control measures of Burkholderia gladioli and its toxins: A review. J Food Sci. 2025;90(2):e17668.
116. Segonds C, Clavel-Batut P, Thouverez M, Grenet D, Le Coustumier A, Plesiat P, et al. Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli. J Clin
Microbiol. 2009;47(5):1510-6.